TRANSLAGE - A UNIFIED PLATFORM TO BUILD AND TRANSLATE AGING BIOMARKERS INTO CLINICAL SURROGATE ENDPOINTS

Sep 29, 2026

TranslAGE is a knowledgebase and clinical trial platform designed to benchmark aging biomarkers for use as clinical surrogate endpoints. It addresses limitations in validation by standardizing three key metrics: Responsiveness, Prognostication, and Reliability. Responsiveness evaluates biomarkers across 51 intervention types, including drugs, supplements, lifestyle changes, and procedures. Prognostication integrates 50,000+ individuals to predict 40+ outcomes, and Reliability tests technical reproducibility and biological variability from real-world factors. The standardized framework supports biomarker selection for globally generalizable geroscience trials.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

TranslAGE platform overview

Benchmarking with RPR metrics

Responsiveness

Prognostication

Reliability

1324 Innovation in Aging, 2025, Vol. 9, No. S2 promise but face limitations: narrow validation efforts, lack of standardization, and population biases. To address these, we developed TranslAGE, a knowledgebase and clinical trial platform that benchmarks aging biomarkers using three key metrics—Responsiveness, Prognostication, and Reliability (RPR). Responsiveness TranslAGE evaluates biomarkers across 51 interventions, including pharmacological agents, supplements, lifestyle modifications, and medical procedures. This breadth enables identification of biomarkers that consistently capture changes in biological age across distinct mechanistic pathways, guiding trials from metabolic health to cellular senescence. Prognostication The platform integrates data from 50,000+ individuals across diverse populations to assess biomarkers’ ability to predict 40+ outcomes—frailty, cognitive decline, cardiovascular disease, and mortality. Unlike prior Western-centric studies, TranslAGE employs standardized metrics to enable cross-population and cross-outcome comparisons, ensuring global relevance. Reliability Utility depends on reproducibility. TranslAGE assesses: Technical reliability using DNA methylation datasets across Illumina 450K, Epic v1, and Epic v2 arrays. Biological reliability by quantifying variability from real-world factors such as circadian timing, stress, and diet—critical for clinical deployment. By uniting these dimensions in a standardized framework, TranslAGE enables shortlisting of biomarkers that are biologically informative, clinically practical, and globally generalizable. This positions the platform as a foundation for advancing the next generation of geroscience clinical trials. Abstract citation ID: igaf122.4406 TRANSLAGE: A UNIFIED PLATFORM TO BUILD AND TRANSLATE AGING BIOMARKERS INTO CLINICAL SURROGATE ENDPOINTS Raghav Sehgal, Yale University, New Haven, Connecticut, United States Evaluating the effectiveness of lifespan- and healthspanextending interventions in human clinical trials requires robust surrogate endpoints. Omics-based aging biomarkers hold

FAQs

What problem does TranslAGE aim to solve in aging biomarker research?

It tackles limitations such as narrow validation efforts, lack of standardization, and population biases when evaluating aging biomarkers for clinical use.

What are the three key metrics used by TranslAGE?

TranslAGE benchmarks biomarkers using Responsiveness, Prognostication, and Reliability (RPR).

How does TranslAGE assess reliability for clinical deployment?

It evaluates technical reliability across DNA methylation array datasets and biological reliability by quantifying variability driven by real-world factors such as circadian timing, stress, and diet.

Sep 29, 2026

Upload by PakDamar76